303 related articles for article (PubMed ID: 33451973)
1. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.
Abrams SL; Akula SM; Martelli AM; Cocco L; Ratti S; Libra M; Candido S; Montalto G; Cervello M; Gizak A; Rakus D; Steelman LS; McCubrey JA
Adv Biol Regul; 2021 Jan; 79():100780. PubMed ID: 33451973
[TBL] [Abstract][Full Text] [Related]
2. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
3. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
4. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Abrams SL; Lertpiriyapong K; Yang LV; Martelli AM; Cocco L; Ratti S; Falasca M; Murata RM; Rosalen PL; Lombardi P; Libra M; Candido S; Montalto G; Cervello M; Steelman LS; McCubrey JA
Adv Biol Regul; 2018 Aug; 69():16-34. PubMed ID: 29980405
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.
Abrams SL; Duda P; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Montalto G; Emma MR; Cervello M; Rakus D; Gizak A; McCubrey JA
Cells; 2022 Feb; 11(5):. PubMed ID: 35269416
[TBL] [Abstract][Full Text] [Related]
6. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Libra M; Falzone L; Candido S; Montalto G; Cervello M; Lombardi P; McCubrey JA
Adv Biol Regul; 2022 Jan; 83():100840. PubMed ID: 34866036
[TBL] [Abstract][Full Text] [Related]
7. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.
McCubrey JA; Abrams SL; Follo MY; Manzoli L; Ratti S; Martelli AM; Cervello M
Adv Biol Regul; 2023 Jan; 87():100917. PubMed ID: 36243652
[TBL] [Abstract][Full Text] [Related]
8. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Abrams SL; Akula SM; Meher AK; Steelman LS; Gizak A; Duda P; Rakus D; Martelli AM; Ratti S; Cocco L; Montalto G; Cervello M; Ruvolo P; Libra M; Falzone L; Candido S; McCubrey JA
Cells; 2021 Apr; 10(4):. PubMed ID: 33917370
[TBL] [Abstract][Full Text] [Related]
9. TP53/miR-34a-associated signaling targets
Akula SM; Ruvolo PP; McCubrey JA
Aging (Albany NY); 2020 Jan; 12(3):2777-2797. PubMed ID: 31986125
[TBL] [Abstract][Full Text] [Related]
10. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells.
Akula SM; Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Cocco L; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Murata RM; Rosalen PL; Bueno-Silva B; Matias de Alencar S; Falasca M; Montalto G; Cervello M; Notarbartolo M; Gizak A; Rakus D; Libra M; McCubrey JA
Adv Biol Regul; 2020 Jan; 75():100672. PubMed ID: 31685431
[TBL] [Abstract][Full Text] [Related]
11. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
12. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
13. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.
McCubrey JA; Abrams SL; Steelman LS; Cocco L; Ratti S; Martelli AM; Lombardi P; Gizak A; Duda P
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204775
[TBL] [Abstract][Full Text] [Related]
14. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
15. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
16. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53.
Swidnicka-Siergiejko AK; Gomez-Chou SB; Cruz-Monserrate Z; Deng D; Liu Y; Huang H; Ji B; Azizian N; Daniluk J; Lu W; Wang H; Maitra A; Logsdon CD
Oncogene; 2017 Jun; 36(22):3149-3158. PubMed ID: 27991926
[TBL] [Abstract][Full Text] [Related]
17. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
18. Metformin influences drug sensitivity in pancreatic cancer cells.
Candido S; Abrams SL; Steelman L; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Lombardi P; Montalto G; Cervello M; Gizak A; Rakus D; Suh PG; Libra M; McCubrey JA
Adv Biol Regul; 2018 May; 68():13-30. PubMed ID: 29482945
[TBL] [Abstract][Full Text] [Related]
19. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
20. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
